ADMA Biologics Inc (ADMA) financial statements (2022 and earlier)

Company profile

Business Address C/O ADMA BIOLOGICS, INC.
RAMSEY, NJ 07446
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments51,08955,92126,75222,75543,10815,30516,809
Cash and cash equivalents51,08955,92126,75222,75543,1089,91510,441
Short-term investments     5,3906,368
Restricted cash and investments    1,500  
Receivables28,57713,2373,4701,3923,8801,018924
Inventory, net of allowances, customer advances and progress billings124,72481,53653,06518,61612,6285,0203,446
Inventory124,72481,53653,06518,61612,6285,0203,446
Other undisclosed current assets4,3393,0462,5341,7662,051314111
Total current assets:208,729153,74185,82044,53063,16721,65721,290
Noncurrent Assets
Operating lease, right-of-use asset7,2634,259 
Property, plant and equipment50,93541,59331,74130,11630,467  
Intangible assets, net (including goodwill)5,2585,9746,6897,5348,379  
Goodwill3,5303,5303,5303,5303,530  
Intangible assets, net (excluding goodwill)1,7292,4443,1594,0044,849  
Deposits noncurrent assets 2,1072,8401,5445102727
Restricted cash and investments   4,0004,000  
Other undisclosed noncurrent assets4,067  1,1541,496  
Total noncurrent assets:67,52353,93341,27044,34744,8522727
Other undisclosed assets     2,0012,397
TOTAL ASSETS:276,253207,673127,09188,877108,01923,68523,715
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities23,41419,43913,6569,4529,2394,9504,056
Accounts payable12,42911,0749,1755,9005,9212,5652,088
Accrued liabilities5,7528,3654,4813,5523,3182,3851,968
Employee-related liabilities5,233      
Deferred revenue143143143
Debt  22930 6,12815
Deferred revenue and credits143  
Other liabilities    58  
Other undisclosed current liabilities6,821366 143 145145
Total current liabilities:30,37819,94714,0289,6259,44011,2234,217
Noncurrent Liabilities
Long-term debt and lease obligation102,32992,96968,29126,56025,36812,34114,283
Long-term debt, excluding current maturities94,86692,96968,29126,44125,36812,32214,247
Capital lease obligations119 2036
Operating lease, liability7,462  
Liabilities, other than long-term debt2,3732,38117,27615,13517,4964,4804,265
Deferred revenue and credits2,5472,6902,833
Accounts payable and accrued liabilities 207     
Deferred revenue1,9762,1192,262
Due to related parties  14,90814,87414,842  
Other liabilities397551072611061,7901,432
Other undisclosed noncurrent liabilities 4,1271,30217,78615,38298129
Total noncurrent liabilities:104,70299,47786,87059,48158,24616,91918,677
Total liabilities:135,080119,424100,89869,10667,68628,14222,894
Stockholders' equity
Stockholders' equity attributable to parent, including:141,17388,24926,19319,77040,333(4,457)821
Common stock201065411
Additional paid in capital553,266428,704290,904236,203191,022102,47688,240
Accumulated deficit(412,113)(340,465)(264,717)(216,437)(150,694)(106,935)(87,420)
Other undisclosed stockholders' equity attributable to parent    1  
Total stockholders' equity:141,17388,24926,19319,77040,333(4,457)821
TOTAL LIABILITIES AND EQUITY:276,253207,673127,09188,877108,01923,68523,715

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues80,94342,22029,34916,98522,76110,6617,178
Revenue, net15,61810,5187,050
Other operating income    7,000  
Cost of revenue(79,769)(61,291)(39,504)(42,195)(2,777)(6,361)(4,311)
Cost of goods and services sold    (29,164)(6,361)(4,311)
Other undisclosed gross profit    (26,387)  
Gross profit:1,173(19,072)(10,155)(25,209)(6,404)4,3002,866
Operating expenses(59,547)(107,135)(70,773)(77,274)(62,071)(27,991)(22,691)
Other undisclosed operating income 61,29139,50442,19529,1646,3614,311
Operating loss:(58,374)(64,915)(41,424)(60,289)(39,310)(17,330)(15,514)
Nonoperating expense(13,274)(10,834)(6,855)(5,455)(4,449)(2,185)(2,456)
Investment income, nonoperating3528811,527   68
Interest and debt expense(13,057)992(9,962)(5,523)(1,210)(2,240)(719)
Loss from continuing operations before equity method investments, income taxes:(84,704)(74,757)(58,242)(71,266)(44,969)(21,755)(18,689)
Other undisclosed income from continuing operations before income taxes     2,240719
Net loss:(84,704)(74,757)(58,242)(71,266)(44,969)(19,515)(17,970)
Other undisclosed net income (loss) attributable to parent13,057(992)9,9625,5231,210  
Net loss available to common stockholders, diluted:(71,648)(75,749)(48,279)(65,743)(43,759)(19,515)(17,970)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(84,704)(74,757)(58,242)(71,266)(44,969)(19,515)(17,970)
Comprehensive loss, net of tax, attributable to parent:(84,704)(74,757)(58,242)(71,266)(44,969)(19,515)(17,970)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: